期刊文献+

吸入制剂用于肺部感染性疾病的研究进展 被引量:1

Research Progress of Inhalation Preparations for Pulmonary Infectious Diseases
原文传递
导出
摘要 近年来,肺部感染性疾病对人类的健康造成了严重威胁。相较于传统的口服和注射给药途径,吸入给药被越来越多地用于治疗肺部感染性疾病。该途径可靶向递送药物至感染部位,具有提高肺部生物利用度、减少全身不良反应和耐药性的优势,因而受到广泛关注。该文概述了用于肺部感染性疾病治疗的吸入制剂的研究进展,以期为肺部吸入用抗感染药物的研发提供参考。 In recent years,pulmonary infectious diseases have posed a serious threat to human health.Compared with the traditional oral and injection administration routes,inhalation administration is increasingly used to treat pulmonary infectious diseases.This route can achieve targeted delivery of drugs to the infected sites,and has the advantages of improving the pulmonary bioavailability,reducing systemic adverse reactions and drug resistance,and therefore has gained widely concern.This paper summarizes the research progress of inhalation preparations for treatment of pulmonary infectious diseases,with a view to providing references for the research and development of anti-infective drugs for pulmonary inhalation.
作者 郭俊彦 吴闻哲 王健 GUO Junyan;WU Wenzhe;WANG Jian(National Advanced Medical Engineering Research Center,China State Institute of Pharmaceutical Industry,Shanghai 201203)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2023年第7期993-1001,共9页 Chinese Journal of Pharmaceuticals
关键词 吸入制剂 肺部感染性疾病 吸入疫苗 吸入装置 inhalation preparation pulmonary infectious disease inhalation vaccine inhaler device
  • 相关文献

参考文献7

二级参考文献60

  • 1霍敏琴,杨梅,游辉,吴海华,吕绍翔,朱家馨.两性霉素B雾化吸入清除下呼吸道真菌定植的研究[J].中华临床医师杂志(电子版),2011,5(13):3909-3911. 被引量:4
  • 2刘爱芹,于学清,刘静.抗流感新药—扎那米韦[J].齐鲁药事,2004,23(8):60-61. 被引量:7
  • 3毛莉萍,孟海涛,钱文斌,麦文渊,金洁.伊曲康唑针剂治疗恶性血液病化疗后深部真菌感染疗效观察[J].中华内科杂志,2005,44(8):618-619. 被引量:12
  • 4血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(修订版)[J].中华内科杂志,2007,46(7):607-610. 被引量:249
  • 5Richardson MD. Changing patterns and trends in systemic fungal infec - tions [J].J Antimicrob Chemother,2005,56 (suppl 1 ) :i5 - i1 1.
  • 6Boogaert M,Winston D J, Bow E J, et al. Intravenous and oral itraconazole versus itravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broadspectrum ntibacterial therapy [ J ]. Ann Intern Med,2001, 135(6) :412 -422.
  • 7Meis JF, Verweij PE. Current management of fungal infections[J]. Drugs,2001,61 Suppl 1:13 -25.
  • 8Braj T, Powederl YWG, Kobyashi GS, et al. Amphotericin B : Current understanding of mechanisms of action [J]. Antib Agents Chcm, 1990, 34:183 - 188.
  • 9BAUGHMAN TM,WRIGHT WL,HUTTON KA.Determination ofzanamivir in rat and monkey plasma by positive ion hydrophilic in-teraction chromatography (HILIC)/tandem mass spectrometry[].Journal of Chromatography B.2007
  • 10ALLEN GD,BROOKES ST,BARROW A,et al.Liquid chromato-graphic-tandem mass spectrometric method for the determination ofthe neuraminidase inhibitor zanamivir (GG167)in human serum[].Journal of Chromatography B.1999

共引文献34

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部